Mirabegron settlement costs and competition
The $90 million settlement (with $75 million amortized) will impact profitability, and potential generic entrants could erode market share.
LUPIN / bear-case history
Track the concerns that keep returning.
Lupin · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
US base business price erosion
Low single-digit price erosion in the US base business persists, which could offset volume gains if new product launches slow.
Biosimilar market competition
Increasing competition in biosimilars, including PBM private labels, could pressure margins despite Lupin's cost advantage.
Elixa development delays
The respiratory product Elixa has faced development delays; management expects material progress only in calendar 2026.
Mirabegron Competition
A third player has settled and may enter the market, potentially pressuring Lupin's market share and margins.
Tolvaptan Patent Expiry
Patent expiry in September 2026 could bring generic competition, impacting US revenue.
Inflationary Pressures
Rising freight and raw material costs due to geopolitical tensions could impact margins, though management has factored this into guidance.
Dapagliflozin 505(b)(2) Launch Delay
Challenges in achieving product PK for the Dapagliflozin 505(b)(2) could delay launch beyond FY27.